RU2013123792A - Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний - Google Patents
Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний Download PDFInfo
- Publication number
- RU2013123792A RU2013123792A RU2013123792/15A RU2013123792A RU2013123792A RU 2013123792 A RU2013123792 A RU 2013123792A RU 2013123792/15 A RU2013123792/15 A RU 2013123792/15A RU 2013123792 A RU2013123792 A RU 2013123792A RU 2013123792 A RU2013123792 A RU 2013123792A
- Authority
- RU
- Russia
- Prior art keywords
- agent
- cancer
- secad
- antibody
- amino acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 58
- 201000010099 disease Diseases 0.000 title claims abstract 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 13
- 230000000771 oncological effect Effects 0.000 title claims abstract 13
- 239000000203 mixture Substances 0.000 title claims 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract 27
- 206010028980 Neoplasm Diseases 0.000 claims abstract 12
- 201000011510 cancer Diseases 0.000 claims abstract 12
- 239000012634 fragment Substances 0.000 claims abstract 7
- 102000000905 Cadherin Human genes 0.000 claims abstract 5
- 108050007957 Cadherin Proteins 0.000 claims abstract 5
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract 4
- 102000018358 immunoglobulin Human genes 0.000 claims abstract 4
- 230000003211 malignant effect Effects 0.000 claims abstract 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract 4
- 125000000539 amino acid group Chemical group 0.000 claims abstract 3
- 239000010755 BS 2869 Class G Substances 0.000 claims abstract 2
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims abstract 2
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 claims abstract 2
- 101710204410 Scaffold protein Proteins 0.000 claims abstract 2
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 230000000890 antigenic effect Effects 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 210000004994 reproductive system Anatomy 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010062038 Lip neoplasm Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 210000000436 anus Anatomy 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 239000006143 cell culture medium Substances 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 210000000936 intestine Anatomy 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 201000006721 lip cancer Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000005001 male reproductive tract Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000001635 urinary tract Anatomy 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 230000025164 anoikis Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000003782 apoptosis assay Methods 0.000 claims 1
- 230000004900 autophagic degradation Effects 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000005522 programmed cell death Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000000107 tumor biomarker Substances 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 238000012800 visualization Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40736710P | 2010-10-27 | 2010-10-27 | |
| US61/407.367 | 2010-10-27 | ||
| PCT/US2011/058076 WO2012058418A2 (en) | 2010-10-27 | 2011-10-27 | Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013123792A true RU2013123792A (ru) | 2014-12-10 |
Family
ID=45994754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013123792/15A RU2013123792A (ru) | 2010-10-27 | 2011-10-27 | Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20130287784A1 (enExample) |
| EP (1) | EP2632489B1 (enExample) |
| JP (1) | JP6243737B2 (enExample) |
| KR (1) | KR20140075639A (enExample) |
| CN (1) | CN103582494A (enExample) |
| AU (1) | AU2011319777B2 (enExample) |
| BR (1) | BR112013010535A2 (enExample) |
| CA (1) | CA2816358A1 (enExample) |
| ES (1) | ES2784385T3 (enExample) |
| MX (2) | MX357167B (enExample) |
| RU (1) | RU2013123792A (enExample) |
| SG (3) | SG189547A1 (enExample) |
| WO (1) | WO2012058418A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9534058B2 (en) | 2012-02-08 | 2017-01-03 | Abbvie Stemcentrx Llc | Anti-CD324 monoclonal antibodies and uses thereof |
| CN104519899A (zh) * | 2012-03-15 | 2015-04-15 | 纽约州立大学研究基金会 | 包含e-钙粘蛋白的细胞外结构域的抑制剂的组合疗法 |
| US9411750B2 (en) | 2012-07-30 | 2016-08-09 | International Business Machines Corporation | Efficient calibration of a low power parallel data communications channel |
| US9474034B1 (en) | 2015-11-30 | 2016-10-18 | International Business Machines Corporation | Power reduction in a parallel data communications interface using clock resynchronization |
| WO2017156463A1 (en) | 2016-03-10 | 2017-09-14 | Cable Television Laboratories, Inc. | Systems and methods for latency reduction |
| US10492104B2 (en) | 2016-03-10 | 2019-11-26 | Cable Television Laboratories, Inc. | Latency reduction in wireless service |
| US10321351B2 (en) | 2017-03-02 | 2019-06-11 | Cable Television Laboratories, Inc. | System and method for grant assignment |
| BR112018075654B1 (pt) | 2016-06-10 | 2022-04-05 | Veritas Biotecnologia Ltda | Anticorpos monoclonais, composições farmacêuticas, linhagem celular de hibridoma, usos dos referidos anticorpos monoclonais e métodos para detectar a expressão de cdh1 |
| US10420085B2 (en) | 2016-10-07 | 2019-09-17 | Cable Television Laboratories, Inc. | System and method for grant assignment |
| US12225536B2 (en) | 2016-10-07 | 2025-02-11 | Cable Television Laboratories, Inc. | System and method for grant assignment |
| EP3791570A4 (en) | 2018-05-11 | 2022-01-26 | Axon Enterprise, Inc. | SYSTEMS AND METHODS OF CROSS-EDITING |
| WO2021141492A1 (en) * | 2020-01-10 | 2021-07-15 | Kling Biotherapeutics B.V. | Epithelial cadherin-specific antibodies |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| KR940009084B1 (ko) | 1988-05-18 | 1994-09-29 | 체크 포인트 시스템스, 인코오퍼레이티드 | 자기 및 공명회로 검출용 안테나 시스템 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| ES2223040T3 (es) | 1991-04-10 | 2005-02-16 | The Scripps Research Institute | Bibliotecas de receptor heterodimerilo que usan fagemidos. |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US6004555A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
| EP0627940B1 (en) | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors |
| US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| AU5669494A (en) * | 1992-11-17 | 1994-06-08 | Yale University | Human homolog of the e-cadherin gene and methods based thereon |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| US6723320B2 (en) * | 1996-07-24 | 2004-04-20 | Gsf Forschungszentrum Fur Umwelt Und Geshundheit Gmbh | Mutations of E cadherin as a basis for the diagnosis and therapy of human malignant tumors |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| AU2002226075A1 (en) * | 2000-10-23 | 2002-05-06 | University Of Kansas | Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion |
| WO2002081655A2 (en) | 2001-03-28 | 2002-10-17 | Children's Medical Center Corporation | Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo |
| US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| WO2004064765A2 (en) | 2003-01-23 | 2004-08-05 | University Of Rochester | Herpesvirus amplicon particles |
| CA2760642A1 (en) * | 2009-05-01 | 2010-11-04 | The University Of Tokyo | Anti-cadherin antibody |
-
2011
- 2011-10-27 SG SG2013032875A patent/SG189547A1/en unknown
- 2011-10-27 WO PCT/US2011/058076 patent/WO2012058418A2/en not_active Ceased
- 2011-10-27 SG SG10201604467PA patent/SG10201604467PA/en unknown
- 2011-10-27 CN CN201180063111.1A patent/CN103582494A/zh active Pending
- 2011-10-27 EP EP11837082.4A patent/EP2632489B1/en active Active
- 2011-10-27 BR BR112013010535A patent/BR112013010535A2/pt not_active Application Discontinuation
- 2011-10-27 AU AU2011319777A patent/AU2011319777B2/en active Active
- 2011-10-27 KR KR1020137013383A patent/KR20140075639A/ko not_active Ceased
- 2011-10-27 ES ES11837082T patent/ES2784385T3/es active Active
- 2011-10-27 SG SG10202100921YA patent/SG10202100921YA/en unknown
- 2011-10-27 RU RU2013123792/15A patent/RU2013123792A/ru not_active Application Discontinuation
- 2011-10-27 US US13/882,078 patent/US20130287784A1/en not_active Abandoned
- 2011-10-27 CA CA2816358A patent/CA2816358A1/en not_active Abandoned
- 2011-10-27 JP JP2013536823A patent/JP6243737B2/ja active Active
- 2011-10-27 MX MX2013004790A patent/MX357167B/es active IP Right Grant
-
2013
- 2013-04-26 MX MX2018007983A patent/MX2018007983A/es unknown
-
2015
- 2015-03-30 US US14/673,539 patent/US20160046701A1/en not_active Abandoned
-
2019
- 2019-01-24 US US16/256,800 patent/US20190352380A1/en not_active Abandoned
-
2021
- 2021-08-19 US US17/406,611 patent/US20210380671A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014500862A (ja) | 2014-01-16 |
| ES2784385T3 (es) | 2020-09-24 |
| SG189547A1 (en) | 2013-05-31 |
| MX2013004790A (es) | 2014-01-17 |
| US20210380671A1 (en) | 2021-12-09 |
| CA2816358A1 (en) | 2012-05-03 |
| EP2632489A4 (en) | 2014-06-18 |
| WO2012058418A3 (en) | 2012-07-19 |
| BR112013010535A2 (pt) | 2017-11-07 |
| SG10201604467PA (en) | 2016-07-28 |
| AU2011319777B2 (en) | 2016-12-08 |
| US20160046701A1 (en) | 2016-02-18 |
| US20190352380A1 (en) | 2019-11-21 |
| MX2018007983A (es) | 2023-02-23 |
| MX357167B (es) | 2018-06-28 |
| CN103582494A (zh) | 2014-02-12 |
| US20130287784A1 (en) | 2013-10-31 |
| EP2632489B1 (en) | 2020-01-15 |
| AU2011319777A1 (en) | 2013-05-23 |
| SG10202100921YA (en) | 2021-03-30 |
| KR20140075639A (ko) | 2014-06-19 |
| EP2632489A2 (en) | 2013-09-04 |
| JP6243737B2 (ja) | 2017-12-06 |
| WO2012058418A2 (en) | 2012-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013123792A (ru) | Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний | |
| JP7664357B2 (ja) | 抗ｍｅｔ抗体、ｍｅｔに結合する二重特異性抗原結合分子およびその使用方法 | |
| JP7219737B2 (ja) | Ｄｐｐ３の定量方法および治療方法 | |
| Hashimoto et al. | Claudin-5-binders enhance permeation of solutes across the blood-brain barrier in a mammalian model | |
| EP2682475B1 (en) | Antibody and antigen recognizing tumor-initiating cells and use thereof | |
| JP2014500862A5 (enExample) | ||
| BR112020000766A2 (pt) | anticorpos anti-cd166 e seus usos | |
| KR20170008202A (ko) | 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체 | |
| BR112019025188A2 (pt) | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos | |
| JP7090545B2 (ja) | Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用 | |
| JP2023133432A (ja) | 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用 | |
| JP2015514062A5 (enExample) | ||
| RU2014141114A (ru) | Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина | |
| US20220119545A1 (en) | Cdcp1-targeted therapies | |
| ES2639227T3 (es) | Anticuerpos anti S100A7 para el tratamiento y diagnóstico de cáncer | |
| CN120040593A (zh) | 抗her2结合分子 | |
| JP2022044827A (ja) | 免疫媒介性がん治療のための組成物及び方法 | |
| US20250264470A1 (en) | Diagnosis, prognosis and treatment of malignant neoplasms | |
| CN109718374B (zh) | Irf3抑制剂在制备yap过度激活的癌症的治疗或预防药物中的用途 | |
| CN121041442A (zh) | 膜型glyr1分子作为胰腺癌治疗靶点的应用 | |
| KR101618518B1 (ko) | 종양 억제자인 ap5m1을 유효성분으로 포함하는 자궁경부암의 항암치료효과 증진용 약학적 조성물 | |
| TW202527984A (zh) | 5t4抗體藥物結合物及其使用之方法 | |
| CN120359042A (zh) | 改善危重病患者肺功能的dpp3抑制剂 | |
| JP6182149B2 (ja) | Ｅｂａｇ９に対するモノクローナル抗体、及びハイブリドーマ、並びにｅｂａｇ９に対するモノクローナル抗体の利用 | |
| JP2020531811A (ja) | 血液内のｇｋｎ１タンパクを利用する胃癌診断 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170918 |